We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01797601
Recruitment Status : Completed
First Posted : February 22, 2013
Last Update Posted : December 3, 2015
Information provided by (Responsible Party):
andreas fritsche, University Hospital Tuebingen

Brief Summary:
The purpose of the study is to investigate whether insulin sensitivity and insulin resistance of the human brain is comparable in all insulin sensitive parts of the brain and whether correlates to other phenotypic information (i.e. whole body insulin sensitivity, BMI, age) of the study participants.

Condition or disease Intervention/treatment
Obesity Diabetes Drug: Human Insulin Drug: Placebo

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Insulinsensitivität Des Menschlichen Zentralnervensystems: Kernspintomographische Untersuchung Mit Intranasaler Gabe Von Insulin
Study Start Date : February 2013
Primary Completion Date : April 2014
Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Human Insulin
Nasal spray
Drug: Human Insulin
160 U of insulin
Placebo Comparator: Placebo solution
Nasal spray
Drug: Placebo
Insulin dilution medium without insulin

Primary Outcome Measures :
  1. Insulin effect on regional brain activity assessed by fMRI [ Time Frame: Change from Baseline to 15 minutes and 60 minutes post spray application ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal routine blood works
  • for women: negative pregnancy test
  • healthy

Exclusion Criteria:

  • Type 2 diabetes
  • pregnancy
  • acute or chronic diseases
  • Pacemakers
  • Artificial heart valves
  • Metal prostheses
  • Implanted magnetic metal parts (screws, ...)
  • Metal fragments
  • Braces
  • insulin pumps
  • Tattoos
  • claustrophobia
  • reduced temperature sensation and / or increased sensitivity to warming of the body
  • Ear disease or an increased sensitivity to loud noises

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01797601

University of Tuebingen
Tuebingen, Germany, 72074
Sponsors and Collaborators
University Hospital Tuebingen
Principal Investigator: Andreas Fritsche, MD Universität Tübingen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: andreas fritsche, Prof. Andreas Fritsche, University Hospital Tuebingen
ClinicalTrials.gov Identifier: NCT01797601     History of Changes
Other Study ID Numbers: Eudra-CT: 2006-002244-29
17/2008AMG1 ( Other Identifier: Ethik-Kommission an der Medizinischen Fakultät der Eberhard-Karls-Universität und am Universitätsklinikum Tübingen )
First Posted: February 22, 2013    Key Record Dates
Last Update Posted: December 3, 2015
Last Verified: December 2015

Additional relevant MeSH terms:
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs